Terns Pharmaceuticals, Inc.

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong

A cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

The obesity space may have another serious entry as Terns Pharmaceuticals, Inc. unveiled Phase I data for its oral, daily GLP-1 agonist TERN-601 on 9 September that indicate competitive weight-loss